BlackRock’s Acceleron Pharma XLRN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2021
Q4 | – | Sell |
-3,972,924
| Closed | -$684M | – | 5935 |
|
|
2021
Q3 | $684M | Sell |
3,972,924
-430,301
| -10% | -$56.3M | 0.02% | 764 |
|
|
2021
Q2 | $553M | Sell |
4,403,225
-225,753
| -5% | -$28.5M | 0.02% | 943 |
|
|
2021
Q1 | $628M | Buy |
4,628,978
+17,164
| +0.4% | +$2.22M | 0.02% | 825 |
|
|
2020
Q4 | $590M | Sell |
4,611,814
-29,191
| -0.6% | -$3.42M | 0.02% | 785 |
|
|
2020
Q3 | $522M | Buy |
4,641,005
+204,593
| +5% | +$20.4M | 0.02% | 728 |
|
|
2020
Q2 | $423M | Sell |
4,436,412
-682,889
| -13% | -$65.8M | 0.02% | 828 |
|
|
2020
Q1 | $460M | Buy |
5,119,301
+231,500
| +5% | +$18M | 0.02% | 640 |
|
|
2019
Q4 | $259M | Sell |
4,887,801
-287,757
| -6% | -$13.1M | 0.01% | 1281 |
|
|
2019
Q3 | $204M | Buy |
5,175,558
+253,678
| +5% | +$11M | 0.01% | 1390 |
|
|
2019
Q2 | $202M | Buy |
4,921,880
+124,369
| +3% | +$5.15M | 0.01% | 1431 |
|
|
2019
Q1 | $223M | Buy |
4,797,511
+368,617
| +8% | +$16.2M | 0.01% | 1338 |
|
|
2018
Q4 | $193M | Buy |
4,428,894
+81,002
| +2% | +$4.05M | 0.01% | 1343 |
|
|
2018
Q3 | $249M | Buy |
4,347,892
+142,823
| +3% | +$7.02M | 0.01% | 1312 |
|
|
2018
Q2 | $204M | Buy |
4,205,069
+175,010
| +4% | +$6.38M | 0.01% | 1441 |
|
|
2018
Q1 | $158M | Sell |
4,030,059
-702,076
| -15% | -$29.8M | 0.01% | 1536 |
|
|
2017
Q4 | $201M | Buy |
4,732,135
+434,123
| +10% | +$16.3M | 0.01% | 1374 |
|
|
2017
Q3 | $160M | Buy |
4,298,012
+292,784
| +7% | +$10.2M | 0.01% | 1529 |
|
|
2017
Q2 | $122M | Buy |
4,005,228
+330,635
| +9% | +$9.58M | 0.01% | 1676 |
|
|
2017
Q1 | $97.3M | Buy |
3,674,593
+3,595,733
| +4,560% | +$94.8M | 0.01% | 1798 |
|
|
2016
Q4 | $2.01M | Buy |
78,860
+43,820
| +125% | +$1.39M | ﹤0.01% | 1229 |
|
|
2016
Q3 | $1.27M | Sell |
35,040
-541
| -2% | -$17.9K | ﹤0.01% | 1396 |
|
|
2016
Q2 | $1.21M | Buy |
35,581
+1,899
| +6% | +$61.7K | ﹤0.01% | 1357 |
|
|
2016
Q1 | $889K | Buy |
33,682
+4,887
| +17% | +$142K | ﹤0.01% | 1397 |
|
|
2015
Q4 | $1.4M | Sell |
28,795
-4,700
| -14% | -$169K | ﹤0.01% | 1207 |
|
|
2015
Q3 | $834K | Buy |
33,495
+400
| +1% | +$12K | ﹤0.01% | 1355 |
|
|
2015
Q2 | $1.05M | Sell |
33,095
-788
| -2% | -$25.4K | ﹤0.01% | 1341 |
|
|
2015
Q1 | $1.29M | Buy |
33,883
+1,600
| +5% | +$63.6K | ﹤0.01% | 1232 |
|
|
2014
Q4 | $1.26M | Buy |
32,283
+31,900
| +8,329% | +$1.11M | ﹤0.01% | 1163 |
|
|
2014
Q3 | $12K | Hold |
383
| – | – | ﹤0.01% | 2623 |
|
|
2014
Q2 | $13K | Buy |
383
+182
| +91% | +$6.09K | ﹤0.01% | 2625 |
|
|
2014
Q1 | $7K | Buy |
+201
| New | +$9.07K | ﹤0.01% | 2955 |
|
BlackRock's XLRN Position: Q4 2021 in Review
BlackRock sold out of Acceleron Pharma (XLRN) in Q4 2021, closing a stake of 3,972,924 shares — an estimated $684M sold.
BlackRock first reported a position in XLRN in Q1 2014 and held it in 31 quarters. The position peaked at $684M in Q3 2021. 1 fund tracked by Wall St. Rank holds XLRN as of Q4 2021.
- BlackRock reported no remaining Acceleron Pharma position as of Q4 2021 after selling out during the quarter.
- BlackRock sold 3,972,924 Acceleron Pharma shares in Q4 2021, an estimated $684M.
- BlackRock first reported a position in Acceleron Pharma in Q1 2014 and held it in 31 quarters.
- BlackRock's Acceleron Pharma position peaked at $684M in Q3 2021.
- 1 fund tracked by Wall St. Rank held Acceleron Pharma as of Q4 2021.
Based on BlackRock's 13F filing for Q4 2021, filed 10 Feb 2022.